Sp100 isoform-specific regulation of human adenovirus 5 gene expression

Journal of Virology

Volumn 88, Issue 11, 2014, Pages 6076-6092

  Berscheminski, Julia ^a   Wimmer, Peter ^a   Brun, Juliane ^a   Ip, Wing Hang ^a   Groitl, Peter ^a   Horlacher, Tim ^a   Jaffray, Ellis ^b   Hay, Ron T ^b   Dobner, Thomas ^a   Schreiner, Sabrina ^a  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DAXX PROTEIN; HETEROCHROMATIN PROTEIN 1; MEMBRANE PROTEIN; PROTEIN ATRX; PROTEIN SP100; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CHROMATIN CONDENSATION; CONTROLLED STUDY; ENZYME REPRESSION; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE LOSS; GENETIC TRANSCRIPTION; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEPLETION; PROTEIN LOCALIZATION; SUMOYLATION; TRANSCRIPTION REGULATION; VIRUS IMMUNITY; VIRUS REPLICATION;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANTIGENS, NUCLEAR; AUTOANTIGENS; CELL LINE; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, VIRAL; HUMANS; IMMUNITY, INNATE; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; LUCIFERASES; NUCLEAR PROTEINS; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; SUMOYLATION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84899888123     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00469-14     Document Type: Article

References (119)

1. Guldner HH, Szostecki C, Grotzinger T, Will H. 1992. IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. J. Immunol. 149:4067-4073.
2. Grotzinger T, Sternsdorf T, Jensen K, Will H. 1996. Interferonmodulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). Eur. J. Biochem. 238:554-560. http://dx. doi. org/10. 1111/j. 1432-1033. 1996. 0554z. x.
3. Lehming N, Le Saux A, Schuller J, Ptashne M. 1998. Chromatin components as part of a putative transcriptional repressing complex. Proc. Natl. Acad. Sci. USA. 95:7322-7326. http://dx. doi. org/10. 1073/pnas. 95. 13. 7322.
4. Szostecki C, Guldner HH, Netter HJ, Will H. 1990. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J. Immunol. 145:4338-4347.
5. Szostecki C, Krippner H, Penner E, Bautz FA. 1987. Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100). Clin. Exp. Immunol. 68:108-116.
6. Szostecki C, Will H, Netter HJ, Guldner HH. 1992. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand. J. Immunol. 36:555-564. http://dx. doi. org/10. 1111/j. 1365-3083. 1992. tb03224. x.
7. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F. 1992. Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. EMBO J. 11:1397-1407.
8. Fagioli M, Alcalay M, Pandolfi PP, Venturini L, Mencarelli A, Simeone A, Acampora D, Grignani F, Pelicci PG. 1992. Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene 7:1083-1091.
9. Xie K, Lambie EJ, Snyder M. 1993. Nuclear dot antigens may specify transcriptional domains in the nucleus. Mol. Cell. Biol. 13:6170-6179.
10. Dent AL, Yewdell J, Puvion-Dutilleul F, Koken MH, de The H, Staudt LM. 1996. LYSP100-associated nuclear domains (LANDs): description of a new class of subnuclear structures and their relationship to PML nuclear bodies. Blood 88:1423-1426.
11. Seeler JS, Marchio A, Losson R, Desterro JM, Hay RT, Chambon P, Dejean A. 2001. Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role ofSUMOmodification. Mol. Cell. Biol. 21:3314-3324. http://dx. doi. org/10. 1128/MCB. 21. 10. 3314-3324. 2001.
12. Guldner HH, Szostecki C, Schroder P, Matschl U, Jensen K, Luders C, Will H, Sternsdorf T. 1999. Splice variants of the nuclear dot-associated Sp100 protein contain homologies to HMG-1 and a human nuclear phosphoprotein-box motif. J. Cell Sci. 112:733-747.
13. Sternsdorf T, Jensen K, Reich B, Will H. 1999. The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J. Biol. Chem. 274:12555-12566. http://dx. doi. org/10. 1074/jbc. 274. 18. 12555.
14. Bottomley MJ, Collard MW, Huggenvik JI, Liu Z, Gibson TJ, Sattler M. 2001. The SAND domain structure defines a novel DNA-binding fold in transcriptional regulation. Nat. Struct. Biol. 8:626-633. http://dx. doi. org/10. 1038/89675.
15. Isaac A, Wilcox KW, Taylor JL. 2006. SP100B, a repressor of gene expression preferentially binds to DNA with unmethylated CpGs. J. Cell. Biochem. 98:1106-1122. http://dx. doi. org/10. 1002/jcb. 20841.
16. Fish PV, Filippakopoulos P, Bish G, Brennan PE, Bunnage ME, Cook AS, Federov O, Gerstenberger BS, Jones H, Knapp S, Marsden B, Nocka K, Owen DR, Philpott M, Picaud S, Primiano MJ, Ralph MJ, Sciammetta N, Trzupek JD. 2012. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J. Med. Chem. 55:9831-9837. http://dx. doi. org/10. 1021/jm3010515.
17. Baker LA, Allis CD, Wang GG. 2008. PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks. Mutat. Res. 647:3-12. http://dx. doi. org/10. 1016/j. mrfmmm. 2008. 07. 004.
18. Seeler JS, Marchio A, Sitterlin D, Transy C, Dejean A. 1998. Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. Proc. Natl. Acad. Sci. USA. 95:7316-7321. http://dx. doi. org/10. 1073/pnas. 95. 13. 7316.
19. Burnett E, Christensen J, Tattersall P. 2001. A consensus DNA recognition motif for two KDWK transcription factors identifies flexiblelength, CpG-methylation sensitive cognate binding sites in the majority of human promoters. J. Mol. Biol. 314:1029-1039. http://dx. doi. org/10. 1006/jmbi. 2000. 5198.
20. Newhart A, Negorev DG, Rafalska-Metcalf IU, Yang T, Maul GG, Janicki SM. 2013. Sp100A promotes chromatin decondensation at a cytomegalovirus-promoter-regulated transcription site. Mol. Biol. Cell 24:1454-1468. http://dx. doi. org/10. 1091/mbc. E12-09-0669.
21. Sternsdorf T, Jensen K, Will H. 1997. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J. Cell Biol. 139:1621-1634. http://dx. doi. org/10. 1083/jcb. 139. 7. 1621.
22. Muller S, Matunis MJ, Dejean A. 1998. Conjugation with the ubiquitinrelated modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17:61-70. http://dx. doi. org/10. 1093/emboj/17. 1. 61.
23. Ascoli CA, Maul GG. 1991. Identification of a novel nuclear domain. J. Cell Biol. 112:785-795. http://dx. doi. org/10. 1083/jcb. 112. 5. 785.
24. Chang KS, Stass SA, Chu DT, Deaven LL, Trujillo JM, Freireich EJ. 1992. Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia. Mol. Cell. Biol. 12:800-810.
25. Kakizuka A, Miller WH, Jr, Umesono K, Warrell RP, Jr, Frankel SR, Murty VV, Dmitrovsky E, Evans RM. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663-674. http://dx. doi. org/10. 1016/0092-8674(91)90112-C.
26. Dyck JA, Maul GG, Miller WH, Jr, Chen JD, Kakizuka A, Evans RM. 1994. A novel macromolecular structure is a target of the promyelocyteretinoic acid receptor oncoprotein. Cell 76:333-343. http://dx. doi. org/10. 1016/0092-8674(94)90340-9.
27. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. 1991. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675-684. http://dx. doi. org/10. 1016/0092-8674 (91)90113-D.
28. Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub MP, Durand B, Lanotte M, Berger R, Chambon P. 1992. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J. 11:629-642.
29. Goddard AD, Borrow J, Solomon E. 1992. A previously uncharacterized gene, PML, is fused to the retinoic acid receptor alpha gene in acute promyelocytic leukaemia. Leukemia 6(Suppl 3):117S-119S.
30. Melnick A, Fruchtman S, Zelent A, Liu M, Huang Q, Boczkowska B, Calasanz M, Fernandez A, Licht JD, Najfeld V. 1999. Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21. Leukemia 13: 1534-1538.
31. Melnick A, Licht JD. 1999. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215.
32. Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C. 1994. The t(15;17) translocation alters a nuclear body in a retinoic acidreversible fashion. EMBO J. 13:1073-1083.
33. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A, Dejean A. 1994. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76:345-356. http://dx. doi. org/10. 1016/0092-8674(94)90341-7.
34. Sternsdorf T, Guldner HH, Szostecki C, Grotzinger T, Will H. 1995. Two nuclear dot-associated proteins, PML and Sp100, are often coautoimmunogenic in patients with primary biliary cirrhosis. Scand. J. Immunol. 42:257-268. http://dx. doi. org/10. 1111/j. 1365-3083. 1995. tb03652. x.
35. Tavalai N, Stamminger T. 2008. New insights into the role of the subnuclear structure ND10 for viral infection. Biochim. Biophys. Acta 1783: 2207-2221. http://dx. doi. org/10. 1016/j. bbamcr. 2008. 08. 004.
36. Lavau C, Marchio A, Fagioli M, Jansen J, Falini B, Lebon P, Grosveld F, Pandolfi PP, Pelicci PG, Dejean A. 1995. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 11: 871-876.
37. Everett RD, Chelbi-Alix MK. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830. http://dx. doi. org/10. 1016/j. biochi. 2007. 01. 004.
38. Geoffroy MC, Chelbi-Alix MK. 2011. Role of promyelocytic leukemia protein in host antiviral defense. J. Interferon Cytokine Res. 31:145-158. http://dx. doi. org/10. 1089/jir. 2010. 0111.
39. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss JF, 3rd, Maul GG. 1999. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147:221-234. http://dx. doi. org/10. 1083/jcb. 147. 2. 221.
40. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. 2006. The mechanisms of PML-nuclear body formation. Mol. Cell 24:331-339. http://dx. doi. org/10. 1016/j. molcel. 2006. 09. 013.
41. Bernardi R, Pandolfi PP. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8:1006-1016. http://dx. doi. org/10. 1038/nrm2277.
42. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP. 2000. Role of SUMO-1-modified PML in nuclear body formation. Blood 95:2748-2752.
43. Boddy MN, Howe K, Etkin LD, Solomon E, Freemont PS. 1996. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13:971-982.
44. Fu C, Ahmed K, Ding H, Ding X, Lan J, Yang Z, Miao Y, Zhu Y, Shi Y, Zhu J, Huang H, Yao X. 2005. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. Oncogene 24: 5401-5413. http://dx. doi. org/10. 1038/sj. onc. 1208714.
45. Seeler JS, Dejean A. 2003. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell Biol. 4:690-699. http://dx. doi. org/10. 1038/nrm1200.
46. Lang M, Jegou T, Chung I, Richter K, Munch S, Udvarhelyi A, Cremer C, Hemmerich P, Engelhardt J, Hell SW, Rippe K. 2010. Threedimensional organization of promyelocytic leukemia nuclear bodies. J. Cell Sci. 123:392-400. http://dx. doi. org/10. 1242/jcs. 053496.
47. Hay RT. 2005. SUMO: a history of modification. Mol. Cell 18:1-12. http://dx. doi. org/10. 1016/j. molcel. 2005. 03. 012.
48. Wimmer P, Schreiner S, Everett RD, Sirma H, Groitl P, Dobner T. 2010. SUMO modification of E1B-55K oncoprotein regulates isoformspecific binding to the tumour suppressor protein PML. Oncogene 29: 5511-5522. http://dx. doi. org/10. 1038/onc. 2010. 284.
49. Wimmer P, Schreiner S, Dobner T. 2012. Human pathogens and the host cell SUMOylation system. J. Virol. 86:642-654. http://dx. doi. org/10. 1128/JVI. 06227-11.
50. Wimmer P, Blanchette P, Schreiner S, Ching W, Groitl P, Berscheminski J, Branton PE, Will H, Dobner T. 2013. Cross-talk between phosphorylation and SUMOylation regulates transforming activities of an adenoviral oncoprotein. Oncogene 32:1626-1637. http://dx. doi. org/10. 1038/onc. 2012. 187.
51. Chelbi-Alix MK, Quignon F, Pelicano L, Koken MHM, de Thé H. 1998. Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J. Virol. 72:1043-1051.
52. Berscheminski J, Groitl P, Dobner T, Wimmer P, Schreiner S. 2013. The adenoviral oncogene E1A-13S interacts with a specific isoform of the tumor suppressor PML to enhance viral transcription. J. Virol. 87:965-977. http://dx. doi. org/10. 1128/JVI. 02023-12.
53. Tatham MH, Rodriguez MS, Xirodimas DP, Hay RT. 2009. Detection of protein SUMOylation in vivo. Nat. Protoc. 4:1363-1371. http://dx. doi. org/10. 1038/nprot. 2009. 128.
54. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. 2002. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. USA. 99:15655-15660. http://dx. doi. org/10. 1073/pnas. 232137699.
55. Everett RD, Parada C, Gripon P, Sirma H, Orr A. 2008. Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J. Virol. 82:2661-2672. http://dx. doi. org/10. 1128/JVI. 02308-07.
56. Mitsudomi T, Oyama T, Gazdar AF, Minna JD, Okabayashi K, Shirakusa T. 1992. Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance. Nihon Geka Gakkai Zasshi 93:944-947.
57. Schreiner S, Bürck C, Glass M, Groitl P, Wimmer P, Kinkley S, Mund A, Everett RD, Dobner T. 2013. Control of human adenovirus type 5 (Ad5) gene expression by cellular Daxx/ATRX chromatin-associated complexes. Nucleic Acids Res. 41:3532-3550. http://dx. doi. org/10. 1093/nar/gkt064.
58. Guldner HH, Szostecki C, Schroder P, Matschl U, Jensen K, Luders C, Will H, Sternsdorf T. 1999. Splice variants of the nuclear dot-associated Sp100 protein contain homologies to HMG-1 and a human nuclear phosphoprotein-box motif. J. Cell Sci. 112:733-747.
59. Muller D, Schreiner S, Schmid M, Groitl P, Winkler M, Dobner T. 2012. Functional cooperation between human adenovirus type 5 early region 4, open reading frame 6 protein, and cellular homeobox protein HoxB7. J. Virol. 86:8296-8308. http://dx. doi. org/10. 1128/JVI. 00222-12.
60. Groitl P, Dobner T. 2007. Construction of adenovirus type 5 early region 1 and 4 virus mutants. Methods Mol. Med. 130:29-39.
61. Kindsmuller K, Schreiner S, Leinenkugel F, Groitl P, Kremmer E, Dobner T. 2009. A 49-kilodalton isoform of the adenovirus type 5 early region 1B 55-kilodalton protein is sufficient to support virus replication. J. Virol. 83:9045-9056. http://dx. doi. org/10. 1128/JVI. 00728-09.
62. Forrester NA, Patel RN, Speiseder T, Groitl P, Sedgwick GG, Shimwell NJ, Seed RI, Catnaigh PO, McCabe CJ, Stewart GS, Dobner T, Grand RJ, Martin A, Turnell AS. 2012. Adenovirus E4orf3 targets transcriptional intermediary factor 1gamma for proteasome-dependent degradation during infection. J. Virol. 86:3167-3179. http://dx. doi. org/10. 1128/JVI. 06583-11.
63. Schreiner S, Martinez R, Groitl P, Rayne F, Vaillant R, Wimmer P, Bossis G, Sternsdorf T, Ruszsics Z, Dobner T, Wodrich H. 2012. Transcriptional activation of the adenoviral genome is mediated by capsid protein. PLoS Pathog. 8:e1002549. http://dx. doi. org/10. 1371/journal. ppat. 1002549.
64. Reich NC, Sarnow P, Duprey E, Levine AJ. 1983. Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNAbinding protein. Virology 128:480-484. http://dx. doi. org/10. 1016/0042-6822(83)90274-X.
65. Sarnow P, Sullivan CA, Levine AJ. 1982. A monoclonal antibody detecting the adenovirus type 5-E1b-58Kd tumor antigen: characterization of the E1b-58Kd tumor antigen in adenovirus-infected and-transformed cells. Virology 120:510-517. http://dx. doi. org/10. 1016/0042-6822(82) 90054-X.
66. Marton MJ, Baim SB, Ornelles DA, Shenk T. 1990. The adenovirus E4 17-kilodalton protein complexes with the cellular transcription factor E2F, altering its DNA-binding properties and stimulating E1Aindependent accumulation of E2 mRNA. J. Virol. 64:2345-2359.
67. Nevels M, Spruss T, Wolf H, Dobner T. 1999. The adenovirus E4orf6 protein contributes to malignant transformation by antagonizing E1Ainduced accumulation of the tumor suppressor protein p53. Oncogene 18:9-17. http://dx. doi. org/10. 1038/sj. onc. 1202284.
68. Kindsmuller K, Groitl P, Hartl B, Blanchette P, Hauber J, Dobner T. 2007. Intranuclear targeting and nuclear export of the adenovirus E1B-55K protein are regulated by SUMO1 conjugation. Proc. Natl. Acad. Sci. USA. 104:6684-6689. http://dx. doi. org/10. 1073/pnas. 0702158104.
69. Wimmer P, Blanchette P, Schreiner S, Ching W, Groitl P, Berscheminski J, Branton PE, Will H, Dobner T. 2013. Cross-talk between phosphorylation and SUMOylation regulates transforming activities of an adenoviral oncoprotein. Oncogene 32:1626-1637. http://dx. doi. org/10. 1038/onc. 2012. 187.
70. Endter C, Hartl B, Spruss T, Hauber J, Dobner T. 2005. Blockage of CRM1-dependent nuclear export of the adenovirus type 5 early region 1B 55-kDa protein augments oncogenic transformation of primary rat cells. Oncogene 24:55-64. http://dx. doi. org/10. 1038/sj. onc. 1208170.
71. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT. 1999. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18:6455-6461. http://dx. doi. org/10. 1093/emboj/18. 22. 6455.
72. Schreiner S, Wimmer P, Sirma H, Everett RD, Blanchette P, Groitl P, Dobner T. 2010. Proteasome-dependent degradation of Daxx by the viral E1B-55K protein in human adenovirus-infected cells. J. Virol. 84: 7029-7038. http://dx. doi. org/10. 1128/JVI. 00074-10.
73. Cuchet D, Sykes A, Nicolas A, Orr A, Murray J, Sirma H, Heeren J, Bartelt A, Everett RD. 2011. PML isoforms I and II participate in PMLdependent restriction of HSV-1 replication. J. Cell Sci. 124:280-291. http://dx. doi. org/10. 1242/jcs. 075390.
74. Doucas V, Ishov AM, Romo A, Juguilon H, Weitzman MD, Evans RM, Maul GG. 1996. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 10:196-207. http://dx. doi. org/10. 1101/gad. 10. 2. 196.
75. Schreiner S, Kinkley S, Bürck C, Mund A, Wimmer P, Schubert T, Groitl P, Will H, Dobner T. 2013. SPOC1-mediated antiviral host cell response is antagonized early in human adenovirus type 5 infection. PLoS Pathog. 9:e1003775. http://dx. doi. org/10. 1371/journal. ppat. 1003775.
76. Yousef AF, Fonseca GJ, Pelka P, Ablack JN, Walsh C, Dick FA, Bazett-Jones DP, Shaw GS, Mymryk JS. 2010. Identification of a molecular recognition feature in the E1A oncoprotein that binds the SUMO conjugase UBC9 and likely interferes with polySUMOylation. Oncogene 29:4693-4704. http://dx. doi. org/10. 1038/onc. 2010. 226.
77. Ledl A, Schmidt D, Muller S. 2005. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene 24:3810-3818. http://dx. doi. org/10. 1038/sj. onc. 1208539.
78. Schreiner S, Burck C, Glass M, Groitl P, Wimmer P, Kinkley S, Mund A, Everett RD, Dobner T. 2013. Control of human adenovirus type 5 gene expression by cellular Daxx/ATRX chromatin-associated complexes. Nucleic Acids Res. 41:3532-3550. http://dx. doi. org/10. 1093/nar/gkt064.
79. Farr A, Roman A. 1992. A pitfall of using a second plasmid to determine transfection efficiency. Nucleic Acids Res. 20:920. http://dx. doi. org/10. 1093/nar/20. 4. 920.
80. Ibrahim NM, Marinovic AC, Price SR, Young LG, Frohlich O. 2000. Pitfall of an internal control plasmid: response of Renilla luciferase (pRLTK) plasmid to dihydrotestosterone and dexamethasone. Biotechniques 29:782-784.
81. Mulholland DJ, Cox M, Read J, Rennie P, Nelson C. 2004. Androgen responsiveness of Renilla luciferase reporter vectors is promoter, transgene, and cell line dependent. Prostate 59:115-119. http://dx. doi. org/10. 1002/pros. 20059.
82. Vesuna F, Winnard P, Jr, Raman V. 2005. Enhanced green fluorescent protein as an alternative control reporter to Renilla luciferase. Anal. Biochem. 342:345-347. http://dx. doi. org/10. 1016/j. ab. 2005. 04. 047.
83. Cuchet-Lourenco D, Boutell C, Lukashchuk V, Grant K, Sykes A, Murray J, Orr A, Everett RD. 2011. SUMO pathway dependent recruitment of cellular repressors to herpes simplex virus type 1 genomes. PLoS Pathog. 7:e1002123. http://dx. doi. org/10. 1371/journal. ppat. 1002123.
84. Shenk T. 2001. Adenoviridae: the viruses and their replication, p 2265-. 2300. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 4th ed. Lippincott Williams& Wilkins, Philadelphia, PA.
85. Puvion-Dutilleul F, Chelbi-Alix MK, Koken M, Quignon F, Puvion E, de The H. 1995. Adenovirus infection induces rearrangements in the intranuclear distribution of the nuclear body-associated PML protein. Exp. Cell Res. 218:9-16. http://dx. doi. org/10. 1006/excr. 1995. 1125.
86. Hoppe A, Beech SJ, Dimmock J, Leppard KN. 2006. Interaction of the adenovirus type 5 E4 Orf3 protein with promyelocytic leukemia protein isoform II is required for ND10 disruption. J. Virol. 80:3042-3049. http://dx. doi. org/10. 1128/JVI. 80. 6. 3042-3049. 2006.
87. La Cour T, Gupta R, Rapacki K, Skriver K, Poulsen FM, Brunak S. 2003. NESbase version 1. 0: a database of nuclear export signals. Nucleic Acids Res. 31:393-396. http://dx. doi. org/10. 1093/nar/gkg101.
88. Leppard KN, Emmott E, Cortese MS, Rich T. 2009. Adenovirus type 5 E4 Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for disruption via a sequence inPMLisoform II that is predicted as a protein interaction site by bioinformatic analysis. J. Gen. Virol. 90: 95-104. http://dx. doi. org/10. 1099/vir. 0. 005512-0.
89. Carvalho T, Seeler JS, Ohman K, Jordan P, Pettersson U, Akusjarvi G, Carmo-Fonseca M, Dejean A. 1995. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J. Cell Biol. 131:45-56. http://dx. doi. org/10. 1083/jcb. 131. 1. 45.
90. Leppard KN, Everett RD. 1999. The adenovirus type 5 E1b 55K and E4 Orf3 proteins associate in infected cells and affect ND10 components. J. Gen. Virol. 80:997-1008.
91. Stracker TH, Lee DV, Carson CT, Araujo FD, Ornelles DA, Weitzman MD. 2005. Serotype-specific reorganization of the Mre11 complex by adenoviral E4orf3 proteins. J. Virol. 79:6664-6673. http://dx. doi. org/10. 1128/JVI. 79. 11. 6664-6673. 2005.
92. Everett RD. 2001. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20:7266-7273. http://dx. doi. org/10. 1038/sj. onc. 1204759.
93. Wimmer P, Schreiner S, Everett RD, Sirma H, Groitl P, Dobner T. 2010. SUMO modification of E1B-55K oncoprotein regulates isoformspecific binding to the tumour suppressor protein PML. Oncogene 29: 5511-5522. http://dx. doi. org/10. 1038/onc. 2010. 284.
94. König C, Roth J, Dobbelstein M. 1999. Adenovirus type 5 E4orf3 protein relieves p53 inhibition by E1B-55-kilodalton protein. J. Virol. 73:2253-2262.
95. Pennella MA, Liu Y, Woo JL, Kim CA, Berk AJ. 2010. Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies. J. Virol. 84:12210-12225. http://dx. doi. org/10. 1128/JVI. 01442-10.
96. Muller S, Dobner T. 2008. The adenovirus E1B-55K oncoprotein induces SUMO modification of p53. Cell Cycle 7:754-758. http://dx. doi. org/10. 4161/cc. 7. 6. 5495.
97. Lethbridge KJ, Scott GE, Leppard KN. 2003. Nuclear matrix localization and SUMO-1 modification of adenovirus type 5 E1b 55K protein are controlled by E4 Orf6 protein. J. Gen. Virol. 84:259-268. http://dx. doi. org/10. 1099/vir. 0. 18820-0.
98. Blanchette P, Cheng CY, Yan Q, Ketner G, Ornelles DA, Dobner T, Conaway RC, Conaway JW, Branton PE. 2004. Both BC-box motifs of adenovirus protein E4orf6 are required to efficiently assemble an E3 ligase complex that degrades p53. Mol. Cell. Biol. 24:9619-9629. http://dx. doi. org/10. 1128/MCB. 24. 21. 9619-9629. 2004.
99. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, Branton PE. 2001. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 15: 3104-3117. http://dx. doi. org/10. 1101/gad. 926401.
100. Querido E, Marcellus RC, Lai A, Charbonneau R, Teodoro JG, Ketner G, Branton PE. 1997. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J. Virol. 71:3788-3798.
101. Sarnow P, Hearing P, Anderson CW, Halbert DN, Shenk T, Levine AJ. 1984. Adenovirus early region 1B 58, 000-dalton tumor antigen is physically associated with an early region 4 25, 000-dalton protein in productively infected cells. J. Virol. 49:692-700.
102. Sarnow P, Ho YS, Williams J, Levine AJ. 1982. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28:387-394. http://dx. doi. org/10. 1016/0092-8674(82)90356-7.
103. Maul GG, Everett RD. 1994. The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICP0. J. Gen. Virol. 75:1223-1233. http://dx. doi. org/10. 1099/0022-1317-75-6-1223.
104. Everett RD, Meredith M, Orr A, Cross A, Kathoria M, Parkinson J. 1997. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 16:1519-1530. http://dx. doi. org/10. 1093/emboj/16. 7. 1519.
105. Maul GG, Guldner HH, Spivack JG. 1993. Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). J. Gen. Virol. 74:2679-2690. http://dx. doi. org/10. 1099/0022-1317-74-12-2679.
106. Burkham J, Coen DM, Hwang CB, Weller SK. 2001. Interactions of herpes simplex virus type 1 with ND10 and recruitment of PML to replication compartments. J. Virol. 75:2353-2367. http://dx. doi. org/10. 1128/JVI. 75. 5. 2353-2367. 2001.
107. Burkham J, Coen DM, Weller SK. 1998. ND10 protein PML is recruited to herpes simplex virus type 1 prereplicative sites and replication com-partments in the presence of viral DNA polymerase. J. Virol. 72:10100-10107.
108. Chelbi-Alix MK, de The H. 1999. Herpes virus induced proteasomedependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18:935-941. http://dx. doi. org/10. 1038/sj. onc. 1202366.
109. Everett RD, Freemont P, Saitoh H, Dasso M, Orr A, Kathoria M, Parkinson J. 1998. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110-and proteasome-dependent loss of several PML isoforms. J. Virol. 72:6581-6591.
110. Muller S, Dejean A. 1999. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 73:5137-5143.
111. Parkinson J, Everett RD. 2000. Alphaherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins. J. Virol. 74:10006-10017. http://dx. doi. org/10. 1128/JVI. 74. 21. 10006-10017. 2000.
112. Kim YE, Lee JH, Kim ET, Shin HJ, Gu SY, Seol HS, Ling PD, Lee CH, Ahn JH. 2011. Human cytomegalovirus infection causes degradation of Sp100 proteins that suppress viral gene expression. J. Virol. 85:11928-11937. http://dx. doi. org/10. 1128/JVI. 00758-11.
113. Full F, Reuter N, Zielke K, Stamminger T, Ensser A. 2012. Herpesvirus saimiri antagonizes nuclear domain 10-instituted intrinsic immunity via an ORF3-mediated selective degradation of cellular protein Sp100. J. Virol. 86:3541-3553. http://dx. doi. org/10. 1128/JVI. 06992-11.
114. Negorev DG, Vladimirova OV, Ivanov A, Rauscher F, 3rd, Maul GG. 2006. Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression. J. Virol. 80:8019-8029. http://dx. doi. org/10. 1128/JVI. 02164-05.
115. Turnell AS, Grand RJ. 2012. DNA viruses and the cellular DNA-damage response. J. Gen. Virol. 93:2076-2097. http://dx. doi. org/10. 1099/vir. 0. 044412-0.
116. Tavalai N, Adler M, Scherer M, Riedl Y, Stamminger T. 2011. Evidence for a dual antiviral role of the major nuclear domain 10 component Sp100 during the immediate-early and late phases of the human cytomegalovirus replication cycle. J. Virol. 85:9447-9458. http://dx. doi. org/10. 1128/JVI. 00870-11.
117. Dinant C, Luijsterburg MS. 2009. The emerging role of HP1 in the DNA damage response. Mol. Cell. Biol. 29:6335-6340. http://dx. doi. org/10. 1128/MCB. 01048-09.
118. Baldeyron C, Soria G, Roche D, Cook AJ, Almouzni G. 2011. HP1alpha recruitment toDNAdamage by p150CAF-1 promotes homologous recombination repair. J. Cell Biol. 193:81-95. http://dx. doi. org/10. 1083/jcb. 201101030.
119. Ling PD, Peng RS, Nakajima A, Yu JH, Tan J, Moses SM, Yang WH, Zhao B, Kieff E, Bloch KD, Bloch DB. 2005. Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. EMBO J. 24: 3565-3575. http://dx. doi. org/10. 1038/sj. emboj. 7600820.